TNYAMEDIUM SIGNALFINANCIAL10-K

TNYA strengthened its balance sheet with meaningfully higher current assets and reduced liabilities while cutting R&D expenses and improving operating losses.

The company appears to be managing cash burn more effectively, with R&D expenses declining 21% while operating cash flow improved substantially. The enhanced liquidity position and reduced total liabilities suggest better financial discipline, though the company remains deeply unprofitable as expected for a clinical-stage gene therapy developer.

Comparing 2026-03-11 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

TNYA's financial position improved notably across multiple metrics, with current assets growing substantially to $105.6M while total liabilities declined 13% to $23.7M. Operating performance showed meaningful progress as R&D expenses fell 21% and operating losses narrowed from $115.9M to $93.3M, with net losses similarly improving to $90.6M. The combination of enhanced liquidity, reduced expenses, and smaller losses indicates more disciplined capital management as the company advances its clinical programs.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+56.7%
$67.4M→$105.6M

Current assets grew 56.7% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-39.7%
$1.0M→$618K

Capex reduced 39.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
+32.8%
$92.9M→$123.3M

Equity base grew 32.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Cash Flow
Cash Flow
+24.6%
-$90.5M→-$68.3M

Operating cash flow grew 24.6% — strong conversion of earnings to cash, healthy business fundamentals.

Total Assets
Balance Sheet
+22.5%
$119.9M→$146.9M

Asset base grew 22.5% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-20.9%
$86.7M→$68.6M

R&D spending cut 20.9% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+19.5%
-$115.9M→-$93.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+18.5%
-$111.1M→-$90.6M

Net income grew 18.5% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
-12.7%
$27.1M→$23.7M

Liabilities reduced 12.7% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-11
PRIOR — 2025-03-10
ADDED
Heart disease remains the leading cause of death in the world.
In the U.S., one person dies from a cardiovascular-related health condition every 34 seconds, a gruesome statistic that translates to one in every three deaths in the U.S each year.
One in 20 adults suffer from congenital heart disease (CHD) and the picture is equally bleak at the other end of the age spectrum, as approximately 40,000 children are born in the U.S every year with CHD, the leading cause of birth defect-related morbidity and mortality.
We are primarily focused on advancing our clinical-stage gene therapy candidates, TN-201, for MYBPC3 -associated hypertrophic cardiomyopathy (HCM), and TN-401, for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Each candidate is currently in Phase 1b/2 clinical testing to establish the safety and efficacy profile of two different doses.
+7 more — sign up free →
REMOVED
In the U.S., one in every five deaths is attributable to heart disease, and an estimated 40,000 infants are born each year with congenital heart conditions.
We are primarily focused on advancing our lead investigational product candidates, TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Each candidate is currently in clinical testing to establish the safety profile of two different doses in adults with disease due to pathogenic/likely pathogenic mutations.
We anticipate that data generated in the next year will inform late-stage development by characterizing each candidates safety and tolerability profile, ability to transduce target heart cells, and produce the lacking protein underlying disease to slow or even halt disease progression.
Early on in our company history, we invested in differentiated capabilities to enable modality agnostic target identification, validation, anchored in human genetics and the use of human disease models.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →